Matthew Zirwas

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Atopic Dermatitis

Top Venues

Dermatology and therapy

American journal of clinical dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Leon Kircik, Matthew Zirwas, Shawn G Kwatra, G Michael Lewitt, Holly Glover, Tomas Chao, Philip M Brown, David S Rubenstein, Anna M Tallman
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis. Dermatology and therapy 14 (1) (2023)
Leon Kircik, Matthew Zirwas, Shawn G Kwatra, G Michael Lewitt, Holly Glover, Tomas Chao, Philip M Brown, David S Rubenstein, Anna M Tallman
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis. Dermatology and therapy 14 (1) (2023)
Leon Kircik, Matthew Zirwas, Shawn G Kwatra, G Michael Lewitt, Holly Glover, Tomas Chao, Philip M Brown, David S Rubenstein, Anna M Tallman
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis. Dermatology and therapy (2023)
Leon Kircik, Matthew Zirwas, Shawn G Kwatra, G Michael Lewitt, Holly Glover, Tomas Chao, Philip M Brown, David S Rubenstein, Anna M Tallman
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis. Dermatology and therapy 14 (1) (2023)
Leon Kircik, Matthew Zirwas, Shawn G Kwatra, G Michael Lewitt, Holly Glover, Tomas Chao, Philip M Brown, David S Rubenstein, Anna M Tallman
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis. Dermatology and therapy 14 (1) (2023)
Jonathan Ian Silverberg, David N Adam, Matthew Zirwas, Sunil Kalia, Jan Gutermuth, Andreas Pinter, Andrew E Pink, Andrea Chiricozzi, Sébastien Barbarot, Thomas Mark, Ann-Marie Tindberg, Stephan Weidinger
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis. American journal of clinical dermatology 23 (4) (2022)